A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

British Journal of Haematology

Volumn 150, Issue 5, 2010, Pages 574-586

  Kügler, Markus ^a   Stein, Christoph ^a   Kellner, Christian ^b   Mentz, Kristin ^a   Saul, Domenica ^a   Schwenkert, Michael ^a   Schubert, Ingo ^a   Singer, Heiko ^a   Oduncu, Fuat ^c   Stockmeyer, Bernhard ^a   MacKensen, Andreas ^a   Fey, Georg H ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CD123; CD33; dual targeting; leukaemia stem cell; single chain Fv triplebody

Indexed keywords

CD123 ANTIGEN; CD33 ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CD33 PROTEIN, HUMAN; DIFFERENTIATION ANTIGEN; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IL3RA PROTEIN, HUMAN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; LEUKOCYTE ANTIGEN; RECOMBINANT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSIS; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; IMMUNOLOGY; NATURAL KILLER CELL; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, IGG; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED; GPI-LINKED PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 77955782190     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08300.x     Document Type: Article

References (69)

1. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmuller, G., Reinhardt, C., Baeuerle, P.A. Kufer, P. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 321, 974 977.
2. Benedict, C.A., MacKrell, A.J. Anderson, W.F. (1997) Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. Journal of Immunological Methods, 201, 223 231.
3. Bonnet, D. Dick, J.E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730 737.
4. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490 1496.
5. Bruenke, J., Fischer, B., Barbin, K., Schreiter, K., Wachter, Y., Mahr, K., Titgemeyer, F., Niederweis, M., Peipp, M., Zunino, S.J., Repp, R., Valerius, T. Fey, G.H. (2004) A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. British Journal of Haematology, 125, 167 179.
6. Buchner, T., Berdel, W.E., Schoch, C., Haferlach, T., Reichle, A., Staib, P., Sauerland, M.C., Woermann, B., Hiddemann, W. the German, A.M.L.C.G. (2005) Therapeutic outcome in prognostic subgroups of de-novo acute myeloid leukemia (AML) and the role of the age factor. A study in 1834 patients of 16 to 84 years. Journal of Clinical Oncology (Meeting Abstracts), 23, 6552.
7. Carter, P.J. (2006) Potent antibody therapeutics by design. Nature Reviews Immunology, 6, 343 357.
8. ten Cate, B., Bremer, E., de Bruyn, M., Bijma, T., Samplonius, D., Schwemmlein, M., Huls, G., Fey, G. Helfrich, W. (2009) A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia, 23, 1389 1397.
9. Daeron, M. (1997) Fc receptor biology. Annual Review of Immunology, 15, 203 234.
10. Dick, J.E. (2008) Stem cell concepts renew cancer research. Blood, 112, 4793 4807.
11. Du, X., Ho, M. Pastan, I. (2007) New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. Journal of Immunotherapy, 30, 607 613.
12. Elsasser, D., Valerius, T., Repp, R., Weiner, G.J., Deo, Y., Kalden, J.R., van de Winkel, J.G., Stevenson, G.T., Glennie, M.J. Gramatzki, M. (1996) HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood, 87, 3803 3812.
13. Estey, E. Dohner, H. (2006) Acute myeloid leukaemia. Lancet, 368, 1894 1907.
14. Feuring-Buske, M., Frankel, A.E., Alexander, R.L., Gerhard, B. Hogge, D.E. (2002) A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Research, 62, 1730 1736.
15. Fleit, H.B., Wright, S.D. Unkeless, J.C. (1982) Human neutrophil Fc gamma receptor distribution and structure. Proceedings of the National Academy of Sciences of the United States of America, 79, 3275 3279.
16. Frankel, A., Liu, J.S., Rizzieri, D. Hogge, D. (2008) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leukaemia & Lymphoma, 49, 543 553.
17. Freeman, S.D., Kelm, S., Barber, E.K. Crocker, P.R. (1995) Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood, 85, 2005 2012.
18. Graf, M., Hecht, K., Reif, S., Pelka-Fleischer, R., Pfister, K. Schmetzer, H. (2004) Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. European Journal of Haematology, 72, 89 106.
19. Guan, Y. Hogge, D.E. (2000) Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia, 14, 2135 2141.
20. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M. Jordan, C.T. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301 2307.
21. Hauswirth, A.W., Florian, S., Printz, D., Sotlar, K., Krauth, M.T., Fritsch, G., Schernthaner, G.H., Wacheck, V., Selzer, E., Sperr, W.R. Valent, P. (2007) Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. European Journal of Clinical Investigation, 37, 73 82.
22. Hiddemann, W., Spiekermann, K., Buske, C., Feuring-Buske, M., Braess, J., Haferlach, T., Schoch, C., Kern, W., Schnittger, S., Berdel, W., Wormann, B., Heinecke, A., Sauerland, C. Buchner, T. (2005) Towards a pathogenesis-oriented therapy of acute myeloid leukemia. Critical Reviews in Oncology/hematology, 56, 235 245. (Pubitemid 41565552)
23. Hope, K.J., Jin, L. Dick, J.E. (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology, 5, 738 743.
24. Hosen, N., Park, C.Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., Krensky, A.M. Weissman, I.L. (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 104, 11008 11013.
25. Huang, S., Chen, Z., Yu, J.F., Young, D., Bashey, A., Ho, A.D. Law, P. (1999) Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues. Stem Cells, 17, 265 272.
26. Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., Tomiyama, H., Saito, N., Fukata, M., Miyamoto, T., Lyons, B., Ohshima, K., Uchida, N., Taniguchi, S., Ohara, O., Akashi, K., Harada, M. Shultz, L.D. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature biotechnology, 25, 1315 1321.
27. Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver, D., van Rooijen, N. Weissman, I.L. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 138, 271 285.
28. Jedema, I., Barge, R.M., van der Velden, V.H., Nijmeijer, B.A., van Dongen, J.J., Willemze, R. Falkenburg, J.H. (2004) Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia, 18, 316 325.
29. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F. Dick, J.E. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine, 12, 1167 1174. (Pubitemid 44527352)
30. Jin, L., Lee, E.M., Ramshaw, H.S., Busfield, S.J., Peoppl, A.G., Wilkinson, L., Guthridge, M.A., Thomas, D., Barry, E.F., Boyd, A., Gearing, D.P., Vairo, G., Lopez, A.F., Dick, J.E. Lock, R.B. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5, 31 42.
31. Jordan, C.T., Upchurch, D., Szilvassy, S.J., Guzman, M.L., Howard, D.S., Pettigrew, A.L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D.A., Luger, S.M. Phillips, G.L. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia, 14, 1777 1784.
32. Kellner, C., Bruenke, J., Stieglmaier, J., Schwemmlein, M., Schwenkert, M., Singer, H., Mentz, K., Peipp, M., Lang, P., Oduncu, F., Stockmeyer, B. Fey, G.H. (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. Journal of Immunotherapy, 31, 871 884.
33. Kipriyanov, S.M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.W., Matys, E.R. Little, M. (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. Journal of Molecular Biology, 293, 41 56.
34. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680 685.
35. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A. Dick, J.E. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645 648.
36. Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E.A., Sievers, E.L., Mineur, P., Bennett, J.M., Berger, M.S., Eten, C.B., Munteanu, M., Loken, M.R., Van Dongen, J.J., Bernstein, I.D. Appelbaum, F.R. (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 16, 1627 1636.
37. Lowenberg, B., Griffin, J.D. Tallman, M.S. (2003) Acute myeloid leukemia and acute promyelocytic leukemia. Hematology/the Education Program of the American Society of Hematology, 1, 82 101.
38. Lowenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H.C., Verdonck, L.F., Ferrant, A., Sonneveld, P., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., Breems, D., de Muijnck, H., Schaafsma, R., Verhoef, G., Dohner, H., Gratwohl, A., Pabst, T., Ossenkoppele, G.J. Maertens, J. (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115, 2586 2591.
39. Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D., Jr., van Rooijen, N. Weissman, I.L. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138, 286 299.
40. Mattes, M.J. (1997) Binding parameters of antibodies reacting with multivalent antigens: functional affinity or pseudo-affinity. Journal of Immunological Methods, 202, 97 101.
41. Meeker, T.C., Miller, R.A., Link, M.P., Bindl, J., Warnke, R. Levy, R. (1984) A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma, 3, 305 320.
42. Moretti, S., Lanza, F., Dabusti, M., Tieghi, A., Campioni, D., Dominici, M. Castoldi, G.L. (2001) CD123 (interleukin 3 receptor alpha chain). Journal of Biological Regulators and Homeostatic Agents, 15, 98 100.
43. Munoz, L., Nomdedeu, J.F., Lopez, O., Carnicer, M.J., Bellido, M., Aventin, A., Brunet, S. Sierra, J. (2001) Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica, 86, 1261 1269.
44. Pluckthun, A. Pack, P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology, 3, 83 105.
45. Ravandi, F. Estrov, Z. (2006) Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clinical Cancer Research, 12, 340 344.
46. Ravetch, J.V. Perussia, B. (1989) Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. Journal of Experimental Medicine, 170, 481 497.
47. van Rhenen, A., Feller, N., Kelder, A., Westra, A.H., Rombouts, E., Zweegman, S., van der Pol, M.A., Waisfisz, Q., Ossenkoppele, G.J. Schuurhuis, G.J. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clinical Cancer Research, 11, 6520 6527.
48. Robak, T. Wierzbowska, A. (2009) Current and emerging therapies for acute myeloid leukemia. Clinical therapeutics, 31 (Pt 2 2349 2370.
49. Roberts, A.W., He, S., Bradstock, K.F., Hertzberg, M.S., Durrant, S.T.S., Ritchie, D., Lewis, I.D., Marlton, P., McLachlan, A.J., Yeadon, T.M., Busfield, S.J., Barnden, M.J., Davis, R., Hosback, S., Mirosa, D., Biondo, M., Bamford, S., DeWitte, M. Basser, R. (2008) A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML. Blood (ASH Annual Meeting Abstracts), 112, 2956.
50. Robinson, M.K., Hodge, K.M., Horak, E., Sundberg, A.L., Russeva, M., Shaller, C.C., von Mehren, M., Shchaveleva, I., Simmons, H.H., Marks, J.D. Adams, G.P. (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. British Journal of Cancer, 99, 1415 1425.
51. Rothdiener, M., Muller, D., Castro, P.G., Scholz, A., Schwemmlein, M., Fey, G., Heidenreich, O. Kontermann, R.E. (2010) Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. Journal of controlled release, 144, 251 258.
52. Sambrook, J., Fritsch, E.F. Maniatis, T. (1989) Molecular Cloning. A Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
53. Schoonjans, R., Willems, A., Schoonooghe, S., Leoen, J., Grooten, J. Mertens, N. (2001) A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomolecular engineering, 17, 193 202.
54. Schwemmlein, M., Peipp, M., Barbin, K., Saul, D., Stockmeyer, B., Repp, R., Birkmann, J., Oduncu, F., Emmerich, B. Fey, G.H. (2006) A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. British Journal of Haematology, 133, 141 151.
55. Shipley, J.L. Butera, J.N. (2009) Acute myelogenous leukemia. Experimental Hematology, 37, 649 658.
56. Sievers, E.L. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert opinion on biological therapy, 1, 893 901.
57. Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678 3684.
58. Singer, H., Kellner, C., Lanig, H., Aigner, M., Stockmeyer, B., Oduncu, F., Schwemmlein, M., Stein, C., Mentz, K., Mackensen, A. Fey, G.H. (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. Journal of Immunotherapy, 33, 599 608.
59. Somasundaram, C., Sundarapandiyan, K., Keler, T., Deo, Y.M. Graziano, R.F. (1999) Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells. Human Antibodies, 9, 47 54.
60. Song, L.P., Cheng, J.L., Wang, X.B., Zhang, Z., Fang, M., Zhou, Z.Y. Huang, H.L. (2003) A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells. Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica, 35, 503 510.
61. Stasi, R. (2008) Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert opinion on biological therapy, 8, 527 540.
62. Stein, C., Kellner, C., Kugler, M., Reiff, N., Mentz, K., Schwenkert, M., Stockmeyer, B., Mackensen, A. Fey, G.H. (2010) Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. British Journal Haematology, 148, 879 889.
63. Taussig, D.C., Pearce, D.J., Simpson, C., Rohatiner, A.Z., Lister, T.A., Kelly, G., Luongo, J.L., Danet-Desnoyers, G.A. Bonnet, D. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood, 106, 4086 4092.
64. Tedder, T.F., Baras, A. Xiu, Y. (2006) Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Seminars in Immunopathology, 28, 351 364.
65. Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., Lo-Coco, F. Peschle, C. (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood, 100, 2980 2988.
66. Testa, U., Riccioni, R., Diverio, D., Rossini, A., Lo Coco, F. Peschle, C. (2004) Interleukin-3 receptor in acute leukemia. Leukemia, 18, 219 226.
67. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M. Tedder, T.F. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. Journal of Experimental Medicine, 199, 1659 1669.
68. Vallera, D.A., Todhunter, D.A., Kuroki, D.W., Shu, Y., Sicheneder, A. Chen, H. (2005) A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clinical Cancer Research, 11, 3879 3888.
69. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937 951.